Delivery Order SPE2DR25D2100-SPE2DR26FA1CR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 150 mL quantities, with a contract ceiling value of $2,802.86. This is a firm fixed-price delivery order with an ultimate completion date of November 18, 2025, with no set-aside designation applied. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—the location of performance for this contract—is a major pharmaceutical...
- The Defense Logistics Agency awarded a $1,314.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60ml), with an ultimate completion date of August 1, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,364.18 delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Quillivant XR 25 mg/5 ml Suspension in a 180 ml quantity. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by November 13, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same municipality. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL) with a ceiling value of $2,328.26 on December 1, 2025, with ultimate completion scheduled for December 2, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a $6,392.32 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on December 10, 2025, with completion scheduled for December 11, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under open competition. The product will be performed from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $4,361.39 to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, with an ultimate completion date of November 25, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,475.27 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. The contract is a firm fixed-price delivery order with no set-aside designation, awarded on January 7, 2026, with an ultimate completion date of January 8, 2026. Performance will be executed from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,164.94 to supply Quillivant XR 25 mg/5 ml suspension in a 60 ml quantity, with an ultimate completion date of November 4, 2025. This competitively awarded, firm fixed-price delivery order was issued on November 3, 2025, with no set-aside designation. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a delivery order valued at $1,577.04 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) on July 29, 2025, with completion scheduled for July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- SPE2DR25D2100Indefinite Delivery Contract
- SPE2DR25D2100-SPE2DR26FA1CRDelivery Order
The Defense Logistics Agency awarded a $1,526.88 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on January 9, 2026, with an ultimate completion date of January 12, 2026. This non-set-aside, firm fixed-price delivery order was performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., a major pharmaceutical distributor serving federal government healthcare systems, particularly the Department of Defense and Veterans Affairs. This delivery order is issued under AmerisourceBergen's parent company's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2031. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling delivery of a broad range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies to support military healthcare programs worldwide. The Quillivant XR product—an extended-release liquid formulation of methylphenidate used to treat attention deficit hyperactivity disorder—reflects the type of neurological and specialty pharmaceutical medications the contractor supplies through this strategic contract vehicle to support military treatment facilities and other federal medical institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 1/8/26 |